International Stem Cell Corp., a
California-based biotechnology company developing novel stem cell based
therapies and biomedical products, today issued a press release to update the
medical and investor communities about its recent experiments. Using animal
models, the company has successfully demonstrated how human parthenogenetic
neural stem cells (ISC-hpNSC) can significantly reduce neurological dysfunction
after a stroke.
“With no approved treatments for
neurological dysfunction, individuals who have suffered a stroke have few
treatment options available beyond physical rehabilitation following recovery,”
stated Ruslan Semechkin Ph.D., the company’s chief scientific officer. “These
new results are highly encouraging, suggesting that ISC-hpNSC may have
significant ability to not only reduce but also reverse these neurological
symptoms of dysfunction. These findings not only broaden the future potential
use of our neural stem cells beyond Parkinson’s disease but also offer hope to
a patient population with a significant unmet medical need.”
Neural stem cells work to repair the
brain in several ways. The cells are attracted to the site of injury and in
response to signals released by the damaged tissue release a range of molecules
that reduce inflammation and trigger the recovery process. Neural stem cells
have the ability to make the various neurological cell types to replace the
dead and dying cells necessary for the formation of new brain tissue. In this
way the hpNSCs act as coordinators of all the various activities necessary to
recover brain function.
ISCO’s stroke program uses the same
neural stem cells as the company’s Parkinson’s disease program, derived from
the company’s human parthenogenetic stem cells using a cGMP method based on the
protocol published in Nature Scientific Reports in March 2013 (click here).
Parthenogenetic neural stem cells have been shown in peer-reviewed publications
to have superior immunological properties to other neural stem cells. The
complete dataset will be presented at an upcoming scientific conference to be
announced separately. Further studies investigating the potential for treating
stroke are planned.
According to the National Stroke Association
stroke is a leading cause of death in the United States, killing nearly 130,000
people each year, and is a leading cause of serious, long-term adult
disability. Approximately 795,000 strokes will occur each year, one occurring
every 40 seconds, and taking a life approximately every four minutes.
Approximately two million brain cells die every minute during stroke,
increasing the risk of permanent brain damage, disability or death. The
estimated direct and indirect cost of stroke in the United States in 2010 is
$73.7 billion.
For more information on International
Stem Cell Corp., visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment